This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (61)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael S. Osato, PhD; Rita Reddy, MS; Siddharta G. Reddy, BS; Rebecca L. Penland, BS; Hoda M. Malaty, MD, PhD; David Y. Graham, MD

Arch Intern Med. 2001;161:1217-1220.

Background  Therapy for Helicobacter pylori is generally empiric despite the fact that resistance to metronidazole and clarithromycin compromise therapeutic efficacy. The aim of this study was to aid clinicians in choosing a course of therapy for H pylori infection in the United States.

Methods  The frequency of primary clarithromycin and metronidazole resistance among H pylori isolated from patients enrolled in US-based clinical trials between 1993 and 1999 was reviewed in relation to patient age, sex, region of the United States, and test method (Etest and 2 agar dilution procedures).

Results  Clarithromycin and metronidazole resistance rates were based on the results of 3439 pretreatment Etest determinations and 3193 agar dilution determinations. Sex and age were available on 900 and 823 individuals, respectively. Metronidazole resistance was 39% by Etest and 21.6% by agar dilution (P<.001). Clarithromycin resistance was 12% by Etest and 10.6% by agar dilution. Amoxicillin or tetracycline resistance was rare. Metronidazole and clarithromycin resistance was more common in women than men (eg, 34.7% vs 22.6% for metronidazole and 14.1% vs 9.7% for clarithromycin (P = .01 and P = .06, respectively). Antibiotic resistance increased gradually up to age 70 years, then declined significantly (P<.05) regardless of test method. Regional differences in antimicrobial resistance did not occur.

Conclusions  While age and sex had significant effects on resistance rates, regional differences were not present. The high prevalence of resistance to metronidazole and clarithromycin may soon require the performance of antimicrobial susceptibility testing of H pylori isolates prior to initiating treatment.

From the Departments of Medicine (Drs Osato, Malaty, and Graham and Mr S. G. Reddy and Mss Reddy and Penland) and Molecular Virology and Microbiology (Dr Graham), Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Tex.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(9):1240.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Proton motive force-dependent efflux of tetracycline in clinical isolates of Helicobacter pylori
Anoushiravani et al.
J Med Microbiol 2009;58:1309-1313.
ABSTRACT | FULL TEXT  

Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of Helicobacter pylori in Bulgaria
Boyanova et al.
J Med Microbiol 2009;58:94-100.
ABSTRACT | FULL TEXT  

Helicobacter pylori and antibiotic resistance
Megraud
Gut 2007;56:1502-1502.
FULL TEXT  

Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication: A Randomized Trial
Vaira et al.
ANN INTERN MED 2007;146:556-563.
ABSTRACT | FULL TEXT  

Helicobacter pylori Detection and Antimicrobial Susceptibility Testing
Megraud and Lehours
Clin. Microbiol. Rev. 2007;20:280-322.
ABSTRACT | FULL TEXT  

Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy
De Francesco et al.
J Antimicrob Chemother 2007;59:783-785.
ABSTRACT | FULL TEXT  

In Vitro Activity of a Novel Antimicrobial Agent, TG44, for Treatment of Helicobacter pylori Infection.
Kamoda et al.
Antimicrob. Agents Chemother. 2006;50:3062-3069.
ABSTRACT | FULL TEXT  

Bactericidal and Morphological Effects of NE-2001, a Novel Synthetic Agent Directed against Helicobacter pylori
Dai et al.
Antimicrob. Agents Chemother. 2005;49:3468-3473.
ABSTRACT | FULL TEXT  

Evaluation of seaFAST, a Rapid Fluorescent In Situ Hybridization Test, for Detection of Helicobacter pylori and Resistance to Clarithromycin in Paraffin-Embedded Biopsy Sections
Morris et al.
J. Clin. Microbiol. 2005;43:3494-3496.
ABSTRACT | FULL TEXT  

16S rRNA Mutations That Confer Tetracycline Resistance in Helicobacter pylori Decrease Drug Binding in Escherichia coli Ribosomes
Nonaka et al.
J. Bacteriol. 2005;187:3708-3712.
ABSTRACT | FULL TEXT  

H pylori antibiotic resistance: prevalence, importance, and advances in testing
Megraud
Gut 2004;53:1374-1384.
FULL TEXT  

Risk factors for primary Helicobacter pylori resistance in Bulgarian children
Boyanova et al.
J Med Microbiol 2004;53:911-914.
ABSTRACT | FULL TEXT  

Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001
Cameron et al.
J Med Microbiol 2004;53:535-538.
ABSTRACT | FULL TEXT  

The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections
McMahon et al.
ANN INTERN MED 2003;139:463-469.
ABSTRACT | FULL TEXT  

High-Level {beta}-Lactam Resistance Associated with Acquired Multidrug Resistance in Helicobacter pylori
Kwon et al.
Antimicrob. Agents Chemother. 2003;47:2169-2178.
ABSTRACT | FULL TEXT  

Real-Time PCR Assay for Rapid and Accurate Detection of Point Mutations Conferring Resistance to Clarithromycin in Helicobacter pylori
Oleastro et al.
J. Clin. Microbiol. 2003;41:397-402.
ABSTRACT | FULL TEXT  

Emergence of Tetracycline Resistance in Helicobacter pylori: Multiple Mutational Changes in 16S Ribosomal DNA and Other Genetic Loci
Dailidiene et al.
Antimicrob. Agents Chemother. 2002;46:3940-3946.
ABSTRACT | FULL TEXT